Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Aflibercept (Eylea) for Retinopathy of Prematurity – Long-term Outcomes
2023-504207-89-00Phase 3Completed
- Sponsor
- Bayer
- Start
- Nov 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 3, open-label, single-arm trial of aflibercept in retinopathy of prematurity (ROP), sponsored by Bayer. Started Nov 2023; status: completed.
02
Drugs
aflibercept
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on 2023-504207-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504207-89-00.